TrialCurveROCS: reconstructed Kaplan–Meier curves
Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Gastroenterol Hepatol. 2021 Feb 19;6(4):292–303. doi: 10.1016/S2468-1253(21)00004-2 |
|---|---|
| DOI | 10.1016/S2468-1253(21)00004-2 |
| Registry | NCT01915693 |
| Phase | Phase 3 |
| Conditions | Oesophageal Cancer |
| Interventions | Radiotherapy |
| Sponsor | Lisette Nixon |
| Enrolment | 220 |
| Source licence | Figure published under CC BY 4.0 |
Dysphagia deterioration-free survival (DDFS)
From figure panel A · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Usual care group 13.2 weeks; EBRT group 14.8 weeks. Survival at 8 weeks: Usual care group 70%; EBRT group 74%. Hazard ratio Usual care group vs EBRT group 0.97 (95% CI 0.72–1.32).
| Arm | N | Events | Median (Weeks) |
|---|---|---|---|
| Usual care group | 102 | 84 | 13.2 |
| EBRT group | 97 | 84 | 14.8 |
- Usual care group vs EBRT group: reconstructed HR 0.97 (95% CI 0.72–1.32)
Landmark survival (reconstructed)
| Time | Usual care group | EBRT group |
|---|---|---|
| 4 wk | 83.2% | 85.4% |
| 8 wk | 70.1% | 73.7% |
| 12 wk | 55.7% | 60.5% |
| 26 wk | 26.8% | 26.2% |
Overall survival
From figure panel B · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Usual care group 19.7 weeks; EBRT group 18.8 weeks. Survival at 8 weeks: Usual care group 83%; EBRT group 85%. Hazard ratio Usual care group vs EBRT group 0.86 (95% CI 0.62–1.18).
| Arm | N | Events | Median (Weeks) |
|---|---|---|---|
| Usual care group | 102 | 76 | 19.7 |
| EBRT group | 97 | 76 | 18.8 |
- Usual care group vs EBRT group: reconstructed HR 0.86 (95% CI 0.62–1.18)
Landmark survival (reconstructed)
| Time | Usual care group | EBRT group |
|---|---|---|
| 4 wk | 92.1% | 94.8% |
| 8 wk | 82.9% | 85.1% |
| 12 wk | 71.5% | 69.9% |
| 26 wk | 43.0% | 39.5% |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/rocs-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/rocs-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Lancet Gastroenterol Hepatol. 2021 Feb 19;6(4):292–303. doi: 10.1016/S2468-1253(21)00004-2 doi:10.1016/S2468-1253(21)00004-2. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/rocs
Report a problem with these data
Related trials
- Preoperative chemoradiotherapy vs chemotherapy in gastric/GEJ cancer: Disease-free survival; Overall survival
- STARGATE: Overall survival; Progression-free survival (blinded central radiologic review)
- Chemoradiotherapy with S-1 in older patients with esophageal cancer: Overall survival; Progression-free survival
- ATTRACTION-2 (2-year update): Overall survival; Progression-free survival
- Gastrectomy and second-line chemotherapy in advanced gastric cancer: Overall survival; Overall survival (IPTW-adjusted); Progression-free survival; Progression
- KEYNOTE-590 (Japanese subgroup, extended follow-up): Overall survival; Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials